Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Freeline Therapeutics Holdings plc

Freeline is a clinical-stage biotechnology company focused on developing transformative gene therapies for chronic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into a patient’s bloodstream. The company is currently advancing FLT201, a highly differentiated gene therapy candidate that delivers a novel transgene, in a Phase 1/2 clinical trial in people with Gaucher disease type 1. Freeline has additional programs in research, including one focused on GBA1-linked Parkinson’s disease that leverages the same novel transgene as FLT201. Freeline is headquartered in the UK and has operations in the United States.

Freeline

Today, on the start of #BlackHistoryMonth, our Chief People Officer Nicole Jones, SPHR reflects on the contributions of Black leaders and recognizes those in her own life who have supported her career.
 
Throughout the month, we look forward to celebrating the rich cultural heritage of the Black community and recognizing their triumphs in the face of adversity.

#MLKDay is an opportunity for us to honor the legacy of Dr. Martin Luther King Jr. and reflect on how we can carry his legacy forward.
 
This year, The King Center’s theme is “It Starts With Me.”
 
Today and every day, we have the opportunity to embrace Dr. King’s values by opening our hearts and minds, showing courage and compassion, and being steadfast in our pursuit for a kinder, more equitable and peaceful world.

From virtual meetups to in-person team dinners, our employees across the UK and US enjoyed some holiday festivities and fun this month!
 
Our virtual “speed networking” event gave employees across our sites a chance to connect socially in smaller groups, as we continue to foster a strong, collaborative, and united culture.
 
This holiday season and new year, we want to extend a special thanks to the patient advocacy groups and Gaucher community who continue to show resilience and support for one another, as well as for the hard work and dedication of our entire team.
 
From all of us at Freeline, we wish you a happy holiday and great start to the new year!

Join us Wednesday, November 29, for an educational webinar on two #Gaucher disease type 1 gene therapy trials currently enrolling participants including our Phase 1/2 GALILEO-1 study.
 
We look forward to discussing these opportunities alongside Prevail Therapeutics and in partnership with the Gaucher Community Alliance and International Gaucher Alliance.
 
Register here: https://lnkd.in/gi73XstY

This week we express our gratitude for our Freeline team and their commitment to science and innovation, and to the Gaucher community whose resiliency continues to inspire our work day in and day out.
 
We hope everyone has a safe and happy Thanksgiving holiday!

Last week Aviva Rosenberg, JD,  co-founder and co-president of the Gaucher Community Alliance joined us to share her perspective on the importance of raising awareness of #gaucherdisease.

Thank you, Aviva, for your time and thoughtful insights!

#rarediseaseawareness

This week, Freeline employees from across the UK and US participated in our first Global Day of Service.
 
- Our teammates in Stevenage sorted, counted and boxed nearly 8,000 books for Kenyan libraries at Just be a Child.
 
- The Boston team volunteered at Community Servings, where they helped prep medically tailored, scratch-made meals for approximately 2,400 chronically and critically ill individuals.
 
- Our employees in New York volunteered at GMHC where they assisted clients and served nearly 180 hot meals.
 
Thank you to all who participated and helped to support our local communities!

That’s a wrap on #ESGCT2023! Thank you to the conference organizers and those attended our oral presentation.

#gaucherdisease

Today Freeline will share new clinical data from its Phase 1/2 clinical trial evaluating FLT201, its novel AAV #genetherapy candidate for #gaucher disease in an oral presentation at the European Society of Gene and Cell Therapy’s annual congress.

Learn more about the study here: https://lnkd.in/gaUunUbv

#ESGCT2023

Gaucher disease is a rare, inherited disorder that can cause debilitating and chronic symptoms for patients.

This #GaucherAwarenessMonth, we’re committed to raising awareness of the burden of the disease and the need for new treatment options. 

#gaucher #gaucherawareness #rarediseases #rarediseaseawareness

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22
revenue
cost of revenue
gross profit
selling and marketing expenses
general and administrative expenses	6.79M -	16.60M 144.49%	26.30M 58.42%	44.57M 69.46%	30.66M 31.22%
selling general and administrative expenses	6.79M -	16.60M 144.49%	26.30M 58.42%	44.57M 69.46%	30.66M 31.22%
research and development expenses	34.19M -	47.04M 37.59%	76.15M 61.87%	95.43M 25.32%	66.20M 30.63%
other expenses	-390K -	-10.60M 2,616.67%	-15.27M 44.12%	-2.09M 86.31%	-1.57M 24.87%
cost and expenses	32.72M -	53.05M 62.15%	87.18M 64.34%	137.91M 58.19%	95.29M 30.91%
operating expenses	32.72M -	53.05M 62.15%	87.18M 64.34%	137.91M 58.19%	95.29M 30.91%
interest expense	151K -				-10.31M -
ebitda	-32.13M -	-51.51M 60.29%	-85.27M 65.54%	-133.14M 56.14%	-97.17M 27.01%
operating income	-40.98M -	-63.64M 55.30%	-102.45M 60.97%	-142.38M 38.98%	-98.45M 30.86%
depreciation and amortization	970K -	12.13M 1,151.03%	17.18M 41.59%	9.24M 46.21%	1.27M 86.23%
total other income expenses net	-390K -	9.88M 2,632.31%	6.26M 36.65%	2.33M 62.76%	9.84M 322.45%
income before tax	-33.26M -	-53.77M 61.68%	-96.19M 78.90%	-140.05M 45.59%	-88.60M 36.73%
income tax expense	27K -	141K 422.22%	129K 8.51%	342K 165.12%	368K 7.60%
net income	-33.28M -	-53.91M 61.97%	-96.32M 78.68%	-140.39M 45.75%	-88.97M 36.63%
weighted average shs out	423.19K -	423.19K 0%	943.52K 122.96%	2.38M 152.28%	59.27M 2,390.11%
weighted average shs out dil	423.19K -	423.19K 0%	943.52K 122.96%	2.38M 152.28%	59.27M 2,390.11%
eps	-78.65 -	-127.39 61.97%	-102.09 19.86%	-58.98 42.23%	-1.50 97.46%
epsdiluted	-78.65 -	-127.39 61.97%	-102.09 19.86%	-58.98 42.23%	-1.50 97.46%

LIFE:FREELINE

Freeline

Last Close

6.48

16/02 20:37

Market Cap

28.28M

Beta: -

Volume Today

5.35K

Avg: -

Preview